Drug Profile

AT 351

Alternative Names: AT-351

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Dec 2024 The undisclosed company seeks approval for AT 351 under the US Food and Drug Administratioṉs 505(b) regulatory pathway (Arecor website, June 05)
30 Dec 2024 The undisclosed company plans to file regulatory application for AT 351, by 2027 (Arecor website, June 2025)
08 Jan 2024 Arecor plans a pre-IND meeting with the US FDA for AT 351 in USA (Arecor website, June 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com